Carhartt, America’s premium work wear brand since 1889, is launching its national fall integrated advertising campaign focused on the brand’s durable water repellent Rain Defender® technology available in select outerwear, sweatshirts, pants and accessories. Beginning today, the multi-week campaign will tout “Trust your gear. Not your weatherman” across multiple broadcast and digital mediums through December.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7104351-carhartt-rain-defender-durable-water-repellent-coat/
The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience includes an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program’s alignment with the United States’ Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is expected to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
“We are very excited to extend our commitment to the Amgen Biotech Experience, a program that began 25 years ago, with the intent to ignite a deep passion for innovation and scientific discovery in students,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “This program, which provides advanced biotech curriculum and professional-grade lab equipment at no cost to schools, has opened countless students’ eyes to the world of biotechnology, fueling potential long term advancements to both medicine and society.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7414055-amgen-biotech-experience-grant/
Crystal Lagoons broke the record for the “World's Largest Crystalline Lagoon” with the completion of its latest project in Egypt.
Twelve Crystal Lagoons totaling 250 acres will be the centerpiece of the $5.5 billion dollar, 1,850-acre development in Citystars Sharm El Sheikh. The record-breaking lagoon is 30 acres of crystal-clear water surrounded by white sandy beaches - perfect for swimming, sailing, kayaking and more.
Citystars Sharm el Sheikh's crystal lagoon get its salt water supply from wells in the middle of the desert that are otherwise useless, allowing for a tropical crystalline lagoon in the desert. In addition, the salt water used in the crystal lagoon features higher levels of purity and will be used for reverse osmosis desalinization processes, lowering the costs of water treatment.
To view the multimedia release go to:
http://www.multivu.com/players/English/7689951-crystal-lagoons-guinness-world-record/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
SAIC, Inc. (NYSE: SAI) today held an Investor Day event in New York City in which the senior leadership team of the planned spin-off company, Science Applications International Corp. (SAIC), presented its business plans and financial objectives.
SAIC, Inc. previously announced plans to create two independent, publicly traded companies. Upon completion of the planned spin-off transaction, the technical, engineering and enterprise IT services business will retain the name SAIC and trade under (NYSE: SAIC), while the government and commercial solutions company will be named Leidos and trade under (NYSE: LDOS).
To view Multimedia News Release, go to http://www.multivu.com/mnr/63326-saic-presents-planned-company-s-business-financial-objectives-investor-day
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced the U.S. Food and Drug Administration (FDA) approval and launch of the Cochlear™ Nucleus® Hybrid Implant System, a revolutionary new hybrid hearing solution that helps people who may hear a little but are still missing a lot, even with their hearing aids. The Nucleus Hybrid System is a unique combination of proven solutions, which allows people to get back what they've been missing by amplifying the low-pitched hearing a person does have while restoring access to the high-pitched hearing they've lost. People who are candidates for the technology no longer have to worry about straining to hear with their hearing aids as the Nucleus Hybrid System will allow them to maximize their hearing in all frequencies.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7150651-cochlear-fda-approval-u-s-launch-cochlear-nucleus-hybrid-implant-system
Hyundai Motor Company today unveiled its G90 premium luxury sedan for the Genesis brand in the U.S. market, the new flagship of the brand’s model line-up. The 2017 G90 will compete at the top of the premium luxury car segment with world-class technological innovations and the highest levels of refinement, convenience and dynamic performance.
Created by the new Prestige Design Group, G90 provides strong indications of the brand’s ‘Athletic Elegance’ design identity that will be evident in future Genesis products. The G90 silhouette is both powerful and refined, from its prominent hood, generous wheelbase, minimized overhangs and sophisticated rear deck surfacing. Inside the cabin, fine materials and textures from around the world meet refined ergonomics to provide occupants with absolute convenience and luxurious comfort.
To view the multimedia release go to:
http://www.multivu.com/players/English/75060510-hyundai-genesis-g90-luxury-sedan/
The Clayton home building group (Clayton) and the Oak Ridge National Laboratory (ORNL) have teamed up with two other companies to design and build a 3-D printed concept home, showcasing the possibilities of 3-D printing and illustrating advancements in energy management. The four entities unveiled this revolutionary achievement in 3-D printing at a ceremony in the Oak Ridge National Laboratory on Sept. 23.
To view the multimedia release go to:
http://www.multivu.com/players/English/7413931-clayton-homes-avoid-refund-regret/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
The National Inventors Hall of Fame (NIHF), in partnership with the United States Patent and Trademark Office (USPTO), announced today the 2015 Hall of Fame Inductees, all of whom have changed the world through human, social and/or economic progress.
Among this year’s class of Inductees is Nobel Prize winner Shuji Nakamura, responsible for the blue light-emitting diode (LED) which enabled the white LED, and the blue laser diode; Jaap Haartsen, the inventor of Bluetooth® technology, now used in 2.7 billion devices and growing; George Alcorn, who furthered deep space exploration with his X-ray spectrometer; Kristina M. Johnson and Gary Sharp, pioneers in display technology related to rear projection television and 3D applications; and duo Ioannis Yannas and John Burke, who have saved the lives of many burn victims with their invention of Artificial Skin.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7430151-nihf-inductees-2015/
At the home of the world-famous Monte Carlo Rally and on the Col de Turini, site of some of racing’s most memorable moments, Groupe Renault today announced plans for a new Alpine sports car, and unveiled the Alpine Vision show car.
“Motorsports and sports cars are deeply rooted in the DNA of Groupe Renault,” Groupe Renault Chairman and CEO Carlos Ghosn said. “Earlier this month we announced our return to Formula One with a Renault team, and today we are announcing Alpine. This is an exciting next step in our strategy to leverage talent and technology between road and track, and we look forward to reaching new customers in the sport premium cars segment.”
The show car Alpine Vision combines sensual design with outstanding agility, true to the great Alpine A110 Berlinette loved and admired by enthusiasts around the world. Alpine Vision is powered by a new 4 cylinder turbocharged engine, built by experts at Renault Sport, and its low weight will allow the car to achieve 0 to 100 km/h in less than 4.5 seconds - the target for the future production model.
Alpine will be managed by a small team of passionate experts within Groupe Renault, with one sole mission – to meet and exceed the expectations of the demanding sport premium customer. Michael van der Sande will lead as Alpine managing director, and Antony Villain will head Alpine design.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7762651-groupe-renault-unveils-plans-for-alpine/
